Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2010-01-22
2011-12-13
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S021300, C530S307000, C530S324000
Reexamination Certificate
active
08076291
ABSTRACT:
The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.
REFERENCES:
patent: 4708934 (1987-11-01), Gilligan et al.
patent: 5175146 (1992-12-01), Basava et al.
patent: 5536812 (1996-07-01), Noda et al.
patent: 2006/0127995 (2006-06-01), Consalvo
patent: 2006/0292672 (2006-12-01), Miller et al.
patent: 2008/0207512 (2008-08-01), Roth et al.
patent: 2008/0274952 (2008-11-01), Soares et al.
patent: 0308067 (1989-03-01), None
patent: 0382403 (1990-08-01), None
patent: WO 2006/083254 (2006-08-01), None
Yang et. al. Synthesis of Salmon Calcitonin Analogs Using F-moc based Chemistry on MBHA Resins. Chinese Chemical Letters vol. 10, No. 7, pp. 549-552 (1999).
Notification of Transmittal of the International Search Report and The Written Opinion of the International Searching Authority dated Jul. 29, 2010, issued in corresponding International Application No. PCT/US2010/021872.
Michael J. Twery, et al., “Analogue separates biological effects of salmon calcitonin on brain and renal cortical membranes,”European Journal of Pharmacology, 155, (1988) 285-292.
T.A. Lutz, et al., “Amylin receptors mediate the anorectic action of salmon calcitonin (sCT),”Peptides, 21 (2000) 233-238.
M.J. Twery, et al., “Neuronal membrane sensitivity to a salmon calcitonin analogue with negligible ability to lower serum calcium,”Neuroscience Letters, 86 (1988) 82-88.
Louis Aronne, et al:, “Progressive Reduction in Body Weight after Treatment with the Amylin Analog Pramlintide in Obese Subjects: A Phase 2, Randomized, Placebo-Controlled, Dose-Escalation Study,”The Journal of Clinical Enodcrinology&Metabolism, 92(8):2977-2983 (2007).
E. Del Prete, et al., “Effects of amylin and salmon calcitonin on feeding and drinking behavior in pygmy goats,”Physiology&Behavior, 75 (2002) 593-599.
Roger D. Reidelberger, et al., “Effects of amylin-related peptides on food intake, meal patterns, and gastric emptying in rats,”Am J Physiol Regulatory Integrative Comp Physiol., 282: R1395-R1404, (2002).
Prasanth K. Chelikani, et al., “Intravenous Infusion of Peptide YY(3-36) Potently Inhibits Food Intake in Rats,”Endocrinology, 146(2):879-888 (2005).
Manfred Hallschmid, et al., “Manipulating central nervous mechanisms of food intake and body weight regulation by intranasal administration of neuropeptides in man,”Physiology&Behavior, 83 (2004) 55-64.
Eva Tavares, et al., “N-Procalcitonin: Central Effects on Feeding and Energy Homeostasis in Rats,”Endocrinology, 148(4):1891-1901 (2007).
Sandra Eiden, et al., “Salmon calcitonin—a potent inhibitor of food intake in states of impaired leptin signalling in laboratory rodents,”Journal of Physiology, (2002), 541.3, pp. 1041-1048.
Peter Y. Wielinga, et al., “The acute effect of amylin and salmon calcitonin on energy expenditure,”Physiology&Behavior, 91 (2007) 212-217.
Prasanth K. Chelikani, et al., “Effects of Intermittent Intraperitoneal Infusion of Salmon Calcitonin on Food Intake and Adiposity in Obese Rats,” Articles in PresS.,Am J Physiol Regul Integr Comp Physiol., (Aug. 29, 2007), doi:10.1152/ajpregu.00386.2007, pp. 1-41.
Nicholas T. Bello, et al., “Salmon calcitonin reduces food intake through changes in meal sizes in male rhesus monkeys,” Articles in PresS,Am J Physiol Regul Integr Comp Physiol, (May 14, 2008), doi:10.1152/ajpregu.90327.2008, pp. 1-25.
Prasanth K. Chelikani, et al., “Intravenous infusion of glucagon-like-peptide-1 potently inhibits food intake, sham feeding, and gastric emptying rats,” Articles in PresS. Am J Physiol Regul Integr Comp Physiol, (Feb. 17, 2005), doi:10:1152/ajpregu.00870.2004, 50 pages.
Mark J. Perlow et al., “Calcitonin Reduces Feeding in Man, Monkey and Rat”,Pharmacology&Behavior, vol. 12, pp. 609-612 (Feb. 1979).
Martha V.L. Ray et al., “Production of Recombinant Salmon Calcitonin by In Vitro Amidation of anEscherichia coliProduced Precursor Peptide”, Biotechnology, vol. 11 (Jan. 1993), pp. 64-70.
Martha V.L. Ray, et al., “Production of salmon calcitonin by direct expression of a glycine-extended precursor inEscherichia coli”, Protein Expression and Purification, 26:249-259 (2002).
Nozer M. Mehta, “Oral Delivery and Recombinant Production of Peptide Hormones, Part II: Recombinant Production of Therapeutic Peptides”, Biopharm. International, (Jul. 2004), pp. 44-46.
C.M. Mack et al., “Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight”, Original Article,International Journal of Obesity,(2009) 1-11.
Gilligan James P.
Mehta Nozer M.
Stern William
Sturmer Amy
Abramson Danielle T.
Dykeman David J.
Greenberg & Traurig, LLP
Gupta Anish
Lieb Jeanette
LandOfFree
Treatment for obesity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment for obesity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment for obesity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4252973